Volume 57, Pages S32-S37 (April 2000)

Slides:

Advertisements

Similar presentations

Evaluation and treatment of coronary artery disease in patients with end-stage renal disease Peter A. McCullough Kidney International Volume 67, Pages.

Advertisements

Volume 68, Issue 5, Pages (November 2005)

Volume 55, Issue 2, Pages (February 1999)

Combination therapy with ACE inhibitors and angiotensin II receptor blockers in chronic renal disease: New therapeutic world beyond blood pressure reduction

Paul W. Eggers, Dorothy Gohdes, Jacqueline Pugh Kidney International

Viper venom for diabetic nephropathy

Anemia management in chronic kidney disease

Volume 83, Issue 3, Pages (March 2013)

Epidemiology of diabetic nephropathy in Spain

Volume 68, Issue 5, Pages (November 2005)

From secondary to primary prevention of progressive renal disease: The case for screening for albuminuria Paul E. De Jong, Barry M. Brenner Kidney International

Francesco Locatelli, Lucia Del Vecchio, Simeone Andrulli, Sara Colzani

Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy Misghina Weldegiorgis, Dick de Zeeuw, Liang Li,

Paul W. Eggers, Dorothy Gohdes, Jacqueline Pugh Kidney International

Volume 67, Issue 6, Pages (June 2005)

Viper venom for diabetic nephropathy

Progression of renal failure and hypertensive nephrosclerosis

Peter Rossing, Philip Hougaard, Hans-Henrik Parving

Haiyan Wang, Luxia Zhang, Jicheng Lv Kidney International

Francesco Paolo Schena Kidney International

Need for better diabetes treatment for improved renal outcome

Volume 70, Pages S21-S25 (December 2006)

Volume 55, Issue 2, Pages (February 1999)

Progression of diabetic nephropathy

Volume 54, Issue 4, Pages (October 1998)

Comorbidity and confounding in end-stage renal disease

Volume 82, Issue 3, Pages (August 2012)

Volume 70, Issue 11, Pages (December 2006)

D. Coyne Kidney International Volume 69, Pages S1-S3 (May 2006)

The epidemiology of chronic kidney disease

Study of Heart and Renal Protection (SHARP)

Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease S. Bianchi, R. Bigazzi, V.M. Campese

Saulo Klahr, Jeremiah J. Morrissey Kidney International

Volume 67, Pages S48-S51 (January 2005)

Elke Wühl, Otto Mehls, Franz Schaefer Kidney International

Volume 65, Issue 6, Pages (June 2004)

Volume 53, Issue 4, Pages (April 1998)

Progression of diabetic nephropathy: Role of plasma homocysteine and plasminogen activator inhibitor-1 Peter Hovind, MD, Lise Tarnow, MD, Peter Rossing,

The kidney, a cardiovascular risk marker, and a new target for therapy

Volume 67, Issue 4, Pages (April 2005)

Volume 67, Pages S52-S54 (January 2005)

Volume 63, Issue 2, Pages (February 2003)

Counteracting progression of renal disease: A look into the future

Lynda Anne Szczech, Ira L. Lazar Kidney International

Volume 74, Issue 5, Pages (September 2008)

Volume 60, Issue 1, Pages (July 2001)

Proteinuria screening for children

Volume 66, Pages S18-S21 (November 2004)

Volume 73, Issue 5, Pages (March 2008)

Volume 80, Issue 10, Pages (November 2011)

Volume 60, Issue 3, Pages (September 2001)

Charles A. Herzog Kidney International

Volume 70, Issue 3, Pages (August 2006)

Volume 61, Issue 2, Pages (February 2002)

Is complement a target for therapy in renal disease?

Volume 67, Issue 5, Pages (May 2005)

Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular.

Volume 66, Pages S7-S10 (November 2004)

Renal replacement therapy in Latin America

Giuseppe Remuzzi, Carlos Chiurchiu, Piero Ruggenenti

Volume 56, Issue 4, Pages (October 1999)

Volume 68, Issue 3, Pages (September 2005)

Renal vascular disease in the elderly

Volume 58, Issue 5, Pages (November 2000)

Volume 57, Issue 2, Pages (October 2000)

Lipoprotein abnormalities in diabetic nephropathy

Volume 54, Pages S112-S119 (December 1998)

Volume 57, Pages S44-S48 (April 2000)

Volume 79, Issue 10, Pages (May 2011)

Antonio Piccoli, Luana Pillon Kidney International

Presentation transcript:

Volume 57, Pages S32-S37 (April 2000) Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy Hendrik Bos, Steen Andersen, Peter Rossing, Dick de Zeeuw, Hans-Henrik Parving, Paul E. de Jong, Gerjan Navis Kidney International Volume 57, Pages S32-S37 (April 2000) DOI: 10.1046/j.1523-1755.2000.07506.x Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 1 Individual antiproteinuric efficacy. In diabetic patients (IDDM), efficacy is presented as percentage change in albuminuria. In nondiabetic patients (NDRD), efficacy is presented as percent change in proteinuria. Symbols are: (•), ACE inhibitor vs. AT1 receptor blockade in IDDM; (▴), ACE inhibitor vs. AT1 receptor blockade in NDRD; (▪), ACE inhibitor vs. NSAID combined with alpha-methyldopa in NDRD. Kidney International 2000 57, S32-S37DOI: (10.1046/j.1523-1755.2000.07506.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 2 Individual antihypertensive efficacy presented as percentage change in diabetic patients (IDDM; •) and in nondiabetic renal disease (NDRD; ▴, ACE inhibitor vs. AT1 receptor blockade; ▪, ACE inhibitor vs. NSAID combined with alpha-methyldopa). Kidney International 2000 57, S32-S37DOI: (10.1046/j.1523-1755.2000.07506.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 3 Individual antiproteinuric responses to the two different doses of ACE inhibitor (A) and AT1 receptor blockade (B) for diabetic (IDDM, •) and nondiabetic patients (▪). The continuous line represents the line of identity. Kidney International 2000 57, S32-S37DOI: (10.1046/j.1523-1755.2000.07506.x) Copyright © 2000 International Society of Nephrology Terms and Conditions